Strategy of offering choice of CRC screening ups adherence

This article originally appeared here.
Share this content:
Strategy of Offering Choice of CRC Screening Ups Adherence
Strategy of Offering Choice of CRC Screening Ups Adherence

(HealthDay News) -- Adherence to colorectal cancer (CRC) screening varies based on the screening strategy, with adherence linked to patient preference and ethnicity/race, according to a study published in the April 9 issue of the Archives of Internal Medicine.

To investigate whether the approach by which screening is recommended influences adherence, John M. Inadomi, M.D., from the University of Washington in Seattle, and colleagues randomly allocated 997 individuals at average risk for development of CRC to receive recommendations for screening. Recommendations were received for fecal occult blood testing (FOBT), colonoscopy, or the patient's choice of FOBT or colonoscopy. The completion of screening within 12 months was assessed as the primary outcome.

The researchers found that 58 percent of participants completed the screening strategy they were assigned to or chose. Screening was completed by 38 percent of those who were recommended to colonoscopy, compared with 67 percent of those recommended to FOBT (P < 0.001) and 69 percent of those given a choice (P < 0.001). Screening was completed significantly more often by Latinos and Asians (primarily Chinese) compared with African-Americans. White participants adhered to colonoscopy more often and nonwhite participants adhered to FOBT more often.

"The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities," the authors write. "These results suggest that patient preferences should be considered when making CRC screening recommendations."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs